Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer

Dirk Rades, Stefan Huttenlocher, Markus Dahlke, Dagmar Hornung, Oliver Blanck, Pham Van Thai, Ngo Thuy Trang, Mai Trong Khoa, Steven E. Schild

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Aim: Two dose groups of patients treated with stereotactic radiosurgery (SRS) alone for 1-3 brain metastases from non-small cell lung cancer (NSCLC) were compared for outcomes. Patients and Methods: Based on the SRS dose administered to the margins of the brain lesions, 46 patients were assigned to groups treated with 15-18 Gy (n=13) or with 20 Gy (n=33). Seven additional factors were investigated: age (<58 vs. >59 years), gender, Karnofsky performance score (KPS 70-80 vs. 90-100), number of brain metastases (1 vs. 2-3), histology (adenocarcinoma vs. other) extracerebral metastases and interval from NSCLC diagnosis to SRS (<6 vs. >6 months). Results: Local control rates for 15-18-Gy and 20-Gy groups were 75% and 92% at one year (p=0.043). SRS dose was significant on multivariate analysis (p=0.030). SRS dose was not associated with freedom from new brain metastases (p=0.24) or survival (p=0.37). Conclusion: SRS with 20 Gy resulted in better control of the irradiated metastases than 15-18 Gy did.

Original languageEnglish (US)
Pages (from-to)7309-7313
Number of pages5
JournalAnticancer research
Volume34
Issue number12
StatePublished - Dec 1 2014

Keywords

  • Brain metastases
  • NSCLC
  • Radiation dose
  • Radiosurgery alone
  • Treatment outcomes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Rades, D., Huttenlocher, S., Dahlke, M., Hornung, D., Blanck, O., Thai, P. V., Trang, N. T., Khoa, M. T., & Schild, S. E. (2014). Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer. Anticancer research, 34(12), 7309-7313.